Cyclosporine 0.05% ophthalmic preparation to aid recovery from loss of corneal sensitivity after LASIK

J Refract Surg. 2008 Apr;24(4):337-43. doi: 10.3928/1081597X-20080401-04.

Abstract

Purpose: To determine whether cyclosporine (0.05%) can safely and effectively accelerate corneal nerve regeneration after LASIK, thereby facilitating faster recovery of corneal sensitivity.

Methods: This prospective, randomized, single-center clinical study comprised 44 eyes of 22 patients scheduled to undergo bilateral LASIK. One eye was randomly assigned to receive cyclosporine drops twice daily for 3 months in addition to standard postoperative LASIK medication. Corneal sensitivity was measured using the Cochet-Bonnet esthesiometer in four areas outside and five areas inside the LASIK flap preoperatively and at 1 day, 1 week, 1 month, and 3 months postoperatively. Safety parameters of best spectacle-corrected visual acuity and the incidence of adverse events were also collected.

Results: For all four points outside the LASIK flap, normal corneal sensitivity was maintained throughout the study. In addition, no significant difference was found between the cyclosporine-treated eyes and the control eyes at these points. All points within the LASIK flap except the point closest to the hinge demonstrated profound corneal hypoesthesia at 1 day, 1 week, and 1 month postoperatively with no differences noted between the control and cyclosporine-treated eyes. These same points had statistically significantly greater corneal sensitivity in the cyclosporine group relative to the control group (P< or =.011) at 3 months postoperatively.

Conclusions: Cyclosporine was shown to significantly improve corneal sensitivity at 3 months after LASIK, which suggests that topical cyclosporine promotes enhanced corneal nerve regeneration.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cornea / innervation*
  • Cyclosporine / administration & dosage*
  • Female
  • Humans
  • Hypesthesia / drug therapy
  • Immunosuppressive Agents / administration & dosage*
  • Keratomileusis, Laser In Situ / methods*
  • Lasers, Excimer*
  • Male
  • Middle Aged
  • Nerve Regeneration / drug effects*
  • Ophthalmic Nerve / physiology
  • Ophthalmic Solutions / administration & dosage*
  • Postoperative Care
  • Prospective Studies
  • Refraction, Ocular / physiology
  • Surgical Flaps
  • Visual Acuity / physiology

Substances

  • Immunosuppressive Agents
  • Ophthalmic Solutions
  • Cyclosporine